FindTrial
Sign In

PF-06741086

BIOLOGICAL6 trials

Sponsors

Pfizer

Conditions

HealthyHemophilia AHemophilia A or BHemophilia BSevere Hemophilia

Phase 1

Dose Escalation Study of PF-06741086 In Healthy Subjects
CompletedNCT02531815
PfizerHealthy
Start: 2015-08-31End: 2016-07-31Updated: 2016-08-12
Study to Evaluate Safety and Tolerability of a Single Dose of PF-06741086 in Chinese Adult Participants With Severe Hemophilia
CompletedNCT04878731
PfizerSevere Hemophilia
Start: 2021-04-16End: 2021-08-10Updated: 2023-07-07

Phase 2

PF-06741086 Multiple Dose Study in Severe Hemophilia
CompletedNCT02974855
PfizerHemophilia A or B
Start: 2017-03-08End: 2018-12-03Updated: 2019-12-04
PF-06741086 Long-term Treatment in Severe Hemophilia
CompletedNCT03363321
PfizerHemophilia A or B
Start: 2018-05-30End: 2020-08-05Updated: 2021-07-27

Phase 3

Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B
CompletedNCT03938792
PfizerHemophilia A, Hemophilia B
Start: 2020-03-09End: 2025-04-29Updated: 2026-08-14
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
RecruitingNCT05145127
PfizerHemophilia A, Hemophilia B
Start: 2021-11-17End: 2030-07-31Target: 245Updated: 2026-07-01

Related Papers

Clinical Pharmacokinetics and Pharmacodynamics of Marstacimab, an Anti-tissue Factor Pathway Inhibitor Monoclonal Antibody, in Adolescent and Adult Participants with Hemophilia.
2026-09-04
Efficacy and Safety of Marstacimab Prophylaxis in Hemophilia A/B With Inhibitors: Results from the Phase 3 BASIS Trial.
2025-12-06
Management of breakthrough bleeds in participants with hemophilia Α or Β without inhibitors receiving marstacimab prophylaxis in the phase 3 BASIS study
Blood2025-11-03
Marstacimab prophylaxis in participants with Hemophilia A or B with inhibitors: Results from the Phase 3 BASIS trial
Blood2025-11-03
Outcomes of marstacimab treatment in adolescent participants with Hemophilia A or B without inhibitors compared with prior routine prophylaxis: Results from the phase 3 BASIS trial
Blood2025-11-03
Characterization of participants with elevated bleeding rates responding to prophylactic marstacimab treatment in the phase 3 BASIS trial
Blood2025-11-03
Long term effect of marstacimab prophylaxis in hemophilia Α and Β on target joints: Results from BASIS and OLE studies
Blood2025-11-03
Marstacimab prophylaxis in hemophilia A/B without inhibitors: results from the phase 3 BASIS trial.
2025-10-012 citations
A Fixed (Weight-independent) Subcutaneous Once-Weekly Dose for Marstacimab, an Anti-TFPI Monoclonal Antibody for the Prophylactic Treatment of Hemophilia Α and B
Blood2024-11-052 citations
Safety Biomarkers in Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B Without Inhibitors Receiving Prophylactic Marstacimab Treatment: Results From the Phase 3 BASIS Trial
Blood2024-11-051 citations
Descriptive Characterization of Bleeding Events in Participants with Severe Hemophilia Α or B without Inhibitors, Receiving Prophylactic Marstacimab Treatment
Blood2024-11-051 citations
Efficacy and Safety of the Anti-Tissue Factor Pathway Inhibitor Marstacimab in Participants with Severe Hemophilia without Inhibitors: Results from the Phase 3 Basis Trial
Blood2023-11-0217 citations
Marstacimab, an Anti-Tissue Factor Pathway Inhibitor, in Participants with Hemophilia Α or B, with and without Inhibitors: An Integrated Analysis of Safety
Blood2023-11-025 citations
Long‐term safety and efficacy of the anti‐tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results
British Journal of Haematology2022-10-1158 citations
A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia
British Journal of Haematology2022-08-2340 citations
Peak Thrombin and D-Dimer Levels in Subjects with Severe Hemophilia Receiving Acute Treatment for Bleeding Episodes Experienced during Prophylactic Marstacimab Treatment
Blood2020-11-04
Antibodies to watch in 2020.
2020-01-01328 citations